Galera Therapeutics Announces Pricing of Initial Public Offering

MALVERN, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $12.00 per share, for total gross proceeds of $60.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Galera. All of the common stock is being offered by Galera. In addition, Galera has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock at the initial public offering price less the underwriting discounts and commissions. Galera’s common stock is expected to begin trading on the Nasdaq Global Market on November 7, 2019, under the ticker symbol “GRTX.” The offering is expected to close on November 12, 2019, subject to customary closing conditions.
BofA Securities, Citigroup and Credit Suisse are acting as joint book-running managers for the offering and BTIG is acting as co-manager for the offering.A registration statement relating to the securities being sold in the offering has been declared effective by the U.S. Securities and Exchange Commission on November 6, 2019. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained, when available, by contacting: BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, by e-mail at, Citigroup Global Markets Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at +1 (800) 831-9146, or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, Eleven Madison Avenue, 3rd Floor, New York, NY 10010, or by telephone at +1 (800) 221-1037, or by email at press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera’s lead product candidate is GC4419 (avasopasem manganese), a highly selective and potent small molecule dismutase mimetic that is designed to rapidly convert superoxide to hydrogen peroxide. GC4419 is being studied in the Phase 3 ROMAN trial for its ability to reduce the duration, incidence and severity of radiation-induced severe oral mucositis in patients with locally advanced head and neck cancer, its lead indication. The FDA granted Fast Track and Breakthrough Therapy designations to GC4419 for the reduction of the duration, incidence and severity of severe oral mucositis induced by radiotherapy. Galera is headquartered in Malvern, PA.
Media Contact:
Heather Anderson
6 Degrees
Investor Contact:
Christopher Degnan
Galera Therapeutics, Inc.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.